KR20020009756A - Manufacturing Method for Ginsenoside Compound K by Enzymatic Reaction - Google Patents
Manufacturing Method for Ginsenoside Compound K by Enzymatic Reaction Download PDFInfo
- Publication number
- KR20020009756A KR20020009756A KR1020000043170A KR20000043170A KR20020009756A KR 20020009756 A KR20020009756 A KR 20020009756A KR 1020000043170 A KR1020000043170 A KR 1020000043170A KR 20000043170 A KR20000043170 A KR 20000043170A KR 20020009756 A KR20020009756 A KR 20020009756A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- compound
- diol
- saponin
- ginsenoside compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/20—Preparation of steroids containing heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
본 발명은 효소적 방법에 의한 진세노사이드 컴파운드 K의 제조방법에 관한 것으로, 보다 상세하게는 인삼사포닌 장내세균 대사산물로서 여러가지 우수한 효능을 지니고 있는 것으로 밝혀져 있는 컴파운드 K는 인삼 성분중에서 함량이 많고 분리하기가 용이한 다이올계 사포닌을 효소적 방법으로 구조전환시켜 인삼 사포닌성분의 장내대사산물인 컴파운드 K를 대량으로 제조하는 방법에 관한 것이다.The present invention relates to a method for preparing ginsenoside compound K by an enzymatic method, and more particularly, compound K, which has been found to have various excellent effects as a ginseng saponin enterobacterial metabolite, has a high content and is isolated from ginseng components. The present invention relates to a method for preparing a large amount of compound K, which is an enteric metabolite of ginseng saponin, by converting a diol-based saponin, which is easy to do, into an enzymatic method.
본 발명은 효소적 방법에 의하여 다이올형 사포닌으로부터 다음 일반식(Ⅰ)로 표시되는 20(S)-프로토파낙사다이올-20-0-베타-디-글루코피라노사이드 (이하co mpound K라 함〕를 제조하는 방법에 관한 것이다.20, the present invention is represented by the following general formula (Ⅰ) from the die olhyeong saponin by enzymatic methods (S) - Prototype wave incident diol -20- 0-beta-D-gluconic nose Llano side (hereinafter referred to as co mpound K It relates to a method of manufacturing.
(Ⅰ)(Ⅰ)
상기 일반식(Ⅰ)의 컴파운드 K는 면역증강작용, 종양혈관신생억제작용 및 암세포침윤 억제작용 등이 있는 성분(대한민국 특허등록 0164266, 하세가와 등, 1998년)으로 알려져 있다.Compound K of the general formula (I) is known as an ingredient (immunity enhancer, tumor angiogenesis inhibitory effect and cancer cell invasion inhibitory effect) (Korea Patent Registration 0164266, Hasegawa et al., 1998).
인삼 특유의 약리활성 사포닌인 진세노사이드 유도체들은 다마란계의 트리테르페노이드인 프로토파낙사다이올 또는 프로토파낙사트라이올에 글루코스, 람노스, 아라비노스 또는 자일로스와 같은 당류가 결합한 화합물들로서 현재까지 고려인삼에서 약 30여종의 유도체들이 밝혀져 있다. 또한 인삼 사포닌은 아글리콘에 결합되어 있는 당의 종류나 결합된 당류의 수 또는 결합위치에 따라 약리효능이 각각 다르다는 것이 이미 밝혀져 있으며, 인삼 중 함량이 많고 분리하기가 용이한 주요 사포닌의 약리효능에 대해서는 많은 연구가 수행되었으나, 미량 사포닌의 약리효능에 관한 연구는 극히 적은 편이다.Ginsenoside derivatives, which are pharmacologically active saponins unique to ginseng, are compounds in which saccharides such as glucose, rhamnose, arabinose or xylose are bound to the dimaran-based triterpenoids, protopanaxanadiol or protopanaxanatriol. To date, about 30 derivatives of Korean ginseng have been identified. In addition, ginseng saponins have already been shown to have different pharmacological effects depending on the type of sugars bound to aglycone, the number of saccharides bound to each other, or the position of binding.Ginseng saponins have a large amount of ginseng and are easy to separate. Although many studies have been conducted, very little research has been conducted on the pharmacological efficacy of trace saponins.
본 발명은 인삼 사포닌성분의 체내 대사산물인 컴파운드 K의 새로운 제조방법에 관한 것으로서 다이올계 인삼사포닌을 경구 투여하게 되면 장내세균, 특히 프리보텔라리스(Prevotellaris)에 의해 대사되어 흡수되며 이들 대사산물이 인삼사포닌의 약효를 나타내는 체내 매개물(The Ginseng Review 10, Kobayashi 등, 1994년)로 밝혀져 있는 데, 화합물 K는 효능실험을 통하여 면역증강작용, 종양혈관신생억제작용 및 암세포침윤 억제작용 등 여러 가지 유효한 효능이 있는 것으로 밝혀지고 있으나 인삼 자체에는 함유되어 있지 않고, 체내 대사산물로서 그 수율도 낮아 일시에 다량의 시료를 얻기가 어려운 실정이다. 인삼 사포닌중 다이올계 사포닌은 함량이 높고 진세노사이드 Rd로 구조전환될 수 있는 구조를 갖고 있어 효소적 방법으로 다이올계 사포닌을 구조전환시켜 진세노사이드 Rd를 고수율로 얻을 수 있는 방법을 밝혀 특허출원(대한민국 특허출원 1998년 제16212호)한 바 있다. 한편 컴파운드 K는 프로토파낙사다이올 사포게닌의 C20위치에 포도당 한 분자가 결합된 성분으로 진세노사이드 Rd 성분의 C20위치에 결합된 포도당 한 분자는 그대로 두고 C3위치에 결합된 포도당 두 분자를 절단할 경우 화합물 K로 전환된다는 점에 착안하여 본 연구를 수행하게 되었다.The invention die when olgye the oral administration of ginsenoside intestinal bacteria, in particular freebo is metabolized by telra less (Prevotellaris) and absorption of these metabolites ginseng relates to a novel process for preparing in vivo metabolic products of the compound K of the ginsenoside components It has been shown to be a mediator of the body showing the efficacy of saponin (The Ginseng Review 10, Kobayashi et al., 1994), and compound K has been tested for efficacy, including various effects of immunopotentiation, tumor angiogenesis, and cancer cell infiltration. Although it is found that there is no ginseng itself, the yield is low as a metabolite in the body, it is difficult to obtain a large amount of samples at one time. Diol-based saponins in ginseng saponins are high in content and have a structure that can be structurally converted to ginsenoside Rd, thereby revealing a method of enzymatically converting diol-based saponins to obtain ginsenoside Rd in high yield. Filed (Korean Patent Application No. 16162, 1998). Compound K is a component in which a molecule of glucose is bound to the C 20 position of the protopanaxadiol sapogenin, and two glucoses linked to the C 3 position are left alone while one molecule of glucose is bound to the C 20 position of the ginsenoside Rd component. The study was carried out with the idea that the cleavage of the molecule converts it to compound K.
종래 홍삼에만 함유되어 있는 미량 사포닌인 진세노사이드 Rh1이나 Rh2를 제조하는 방법으로서 산 가수분해법이 개발되어 있다(대한민국 특허등록 제82730호; 대한민국 특허등록 제186757호). 그러나 산 가수분해법은 진세노사이드의 아글리콘 C20위치의 배당체 결합을 분해하기 때문에 산 가수분해법으로 프로토파낙사다이올의 C20위치에 글루코스가 1분자 결합된 형태인 컴파운드 K를 제조하기는 어렵다.또한 종래 컴파운드 K의 제조방법으로서 다이올계 사포닌을 효소인 나린지나제로 가수분해시켜 제조하거나 쥐에 경구투여후 대장에서 분해산물로 생성되는 화합물 K를 분리한 바 있으나 생성 수율이 극히 낮을 뿐만 아니라 여러가지 2차 대사산물이 생성되기 때문에 컴파운드 K를 고순도로 정제하는데 어려움이 있다 (Chem. Pharm. Bull. 38, 2859, Karikura 등, 1990년). 예로서 다이올계 사포닌 분획 5g을 장내세균과 반응시킨 후 대사산물로부터 컴파운드 K 320㎎을 분리한바 있다(생약학회지 26, 360, 성종환 등, 1995년).An acid hydrolysis method has been developed as a method for preparing ginsenosides Rh 1 and Rh 2 , which are trace amounts of saponins contained only in red ginseng (Korean Patent Registration No. 8830; Korean Patent Registration No. 186757). However, acid hydrolysis is difficult to manufacture the ginsenoside of aglycon C 20 in an due to decomposing a glycoside bond to the location in the C 20 position of the protocol-wave incident diol by acid hydrolysis glucose per molecule bonded form compound K In addition, as a conventional method of preparing compound K, diol-based saponins are prepared by hydrolysis with enzyme naringinase or compound K produced as a degradation product in the large intestine after oral administration to rats. Difficult to purify compound K with high purity because secondary metabolites are produced (Chem. Pharm. Bull. 38, 2859, Karikura et al., 1990). For example, 5 g of a diol-based saponin fraction was reacted with enterobacteriaceae and compound K 320 mg was isolated from the metabolite (National Journal of Pharmacognosy 26, 360, Seong Jong-hwan, 1995).
본 발명자들은 효소적 방법에 의해 인삼 중에 함량이 높은 다이올계 사포닌으로부터 컴파운드 K의 제조방법을 개발할 목적으로 각종 미생물에서 분리한 효소를 사용하여 다각적인 시험을 실시한 결과 페니실리움속에서 분리한 셀룰라제와 아스퍼질러스속에서 분리한 베타-갈락토시다제를 진세노사이드 Rb1,Rb2, Rc, Rd 또는 이들의 혼합물과 반응시켰을 때 제조수율 75% 이상의 고수율로 컴파운드 K를 생성한다는데 착안하여 본 발명을 완성하게 되었다.The present inventors conducted various tests using enzymes isolated from various microorganisms for the purpose of developing a method for preparing Compound K from diol-based saponins having high content in ginseng by enzymatic methods. Cellulase isolated from penicillium When the beta-galactosidase isolated from the genus and Aspergillus was reacted with ginsenosides Rb 1, Rb 2 , Rc, Rd or mixtures thereof, the compound K was produced in a high yield of 75% or more. The present invention has been completed.
본 발명은 인삼에 다량 함유되어 있는 주요 다이올계 사포닌인 진세노사이드 Rb1, Rb2, Rc, Rd 및 이들의 혼합물 또는 다이올계 사포닌 함량이 높은 각종 인삼 추출물을 효소적 방법으로 구조전환시켜 컴파운드 K를 간단하게 대량으로 제조하는 데 있다.The present invention is a compound K by ginsenoside Rb 1 , Rb 2 , Rc, Rd, a major diol-containing saponin contained in ginseng, and a mixture thereof or various ginseng extracts having a high diol saponin content by enzymatic method to convert the compound K. It is simply to manufacture in large quantities.
본 발명에서는 인삼의 주요 다이올계 사포닌인 진세노사이드 Rb1, Rb2, Rc, Rd 또는 이들의 혼합물을 물, 인산 또는 시트레이트-인산과 같은 완충용액과 수성용매 또는 수성용매와 유기용매의 혼합액 중에서 페니실리움속에서 분리한 셀룰라제 또는 아스퍼질러스속에서 분리한 베타-갈락토시다제와 함께 반응시키면 단기간 내에 아글리콘 C3위치의 글루코스 두 분자와 C20위치에서 글루코스 1분자를 제외한 나머지 배당체 결합이 용이하게 절단되어 컴파운드 K가 고수율로 생성된다.In the present invention, ginsenosides Rb 1 , Rb 2 , Rc, Rd or a mixture thereof, which is the main diol-based saponin of ginseng, is mixed with a buffer solution such as water, phosphoric acid or citrate-phosphoric acid, and an aqueous solvent or an aqueous solvent and an organic solvent. When reacted with cellulase isolated from penicillium or beta-galactosidase isolated from genus Aspergillus, the glycosides of two molecules of glucose at the aglycone C 3 position and one molecule of glucose at the position C 20 were shortly reacted. The bond is easily cleaved, resulting in a high yield of compound K.
본 발명에 사용되는 용매로는 물, 완충용액과 같은 효소의 활성을 저하시키지 않는 수성용매를 사용하는 것이 좋다. 가장 바람직한 수성용매로는 pH 4∼8, 특히 pH 4∼6범위의 완충용액이 바람직하다. 전술한 수성용매는 단독으로 사용할 수도 있으나 다른 수성용매 및 유기용매와 혼합하여 사용할 수도 있는데, 혼합하여 사용할 수 있는 유기용매는 물과 혼화되면서 효소의 활성을 저하시키지 않는 것이어야 한다. 바람직한 유기용매로는 아세토니트릴, 디옥산, 디메틸 설폭사이드, 메탄올, 에탄올, 1-프로판올, 2-프로판올 등이 있으며, 유기용매의 사용량은 사용한 기질을 기준으로 1∼50% 농도, 특히 2∼30% 농도가 되도록 하는 것이 바람직하다.As the solvent used in the present invention, it is preferable to use an aqueous solvent which does not lower the activity of enzymes such as water and a buffer solution. As the most preferred aqueous solvent, a buffer solution having a pH of 4 to 8, particularly a pH of 4 to 6 is preferable. The above-mentioned aqueous solvent may be used alone, or may be used in combination with other aqueous solvents and organic solvents. The organic solvents that may be used in admixture should not be degrading the activity of the enzyme while being mixed with water. Preferred organic solvents include acetonitrile, dioxane, dimethyl sulfoxide, methanol, ethanol, 1-propanol, 2-propanol, and the like. The amount of the organic solvent used is 1-50% based on the substrate used, particularly 2-30. It is desirable to have a% concentration.
본 발명에 사용되는 효소로는 페니실리움속에서 분리한 셀루라제와 아스퍼질러스속에서 분리한 베타-갈락토시다제가 있으며, 이러한 효소의 첨가방법은 효소의 불활성화가 일어나지 않는 방법이라면 특별히 제한을 받지 않는다.Enzymes used in the present invention include cellulase isolated in the penicillium and beta-galactosidase isolated in the Aspergillus, the addition method of these enzymes is not particularly limited as long as the enzyme inactivation does not occur. Do not receive.
반응온도는 효소의 불활성화가 일어나지 않는 온도조건이어야 하는데, 수성용매만을 사용하는 경우는 60℃ 이하가 바람직하고, 수성용매와 유기용매의 혼합액을 사용하는 경우는 40℃ 이하가 바람직하다. 본 발명에 사용되는 반응시간 역시 효소의 활성이 유지되는 기간이라면 특별히 제한을 받지 않으나 1∼72시간, 바람직하게는 24∼48시간이 적당하다.The reaction temperature should be a temperature condition at which enzyme inactivation does not occur. When only an aqueous solvent is used, 60 ° C. or lower is preferable, and when a mixed solution of an aqueous solvent and an organic solvent is used, 40 ° C. or lower is preferable. The reaction time used in the present invention is not particularly limited as long as the activity of the enzyme is maintained, but is preferably 1 to 72 hours, preferably 24 to 48 hours.
본 발명에 의한 컴파운드 K의 제조방법을 구체적으로 설명하면 다음과 같다. 진세노사이드 Rb1, Rb2, Rc, Rd 또는 이들의 혼합물 및 이들의 함유비율이 높은 인삼 추출물을 수성용매 또는 수성용매와 유기용매의 혼합액에 용해시키고 미생물 페니실리움속에서 유래한 셀룰라제 또는 아스퍼질러스속에서 분리한 베타-갈락토시다제를 가하고 20∼60℃에서 1∼72시간 반응시킨 후 비등 수욕조에서 10분간 가열하여 효소를 불활성화시켜 컴파운드 K가 다량 함유된 반응액을 얻는다. 이와 같은 효소적 방법에 의하면 종래에는 고순도의 진세노사이드 표준품을 효소 헤스페리디나제, 나린지나제, 펙티나제와 반응시켜 제조하거나 또는 사포닌의 장내 대사산물로부터 분리 제조하여 얻었으나 본 방법에서는 반응의 기질인 진세노사이드 Rb1, Rb2, Rc, Rd 등을 고순도의 순품으로 분리해야 하는 어려운 과정을 거치지 않고 사포닌 혼합물을 페니실리움속에서 분리한 효소 셀루라제 또는 아스퍼질러스속에서 분리한 효소인 베타-갈락토시다제와 반응시키면 단기간내에 컴파운드 K만이 주로 생성되기 때문에 분리하기가 용이한 장점이 있다. 본 발명에 의해 제조된 생성물은 다음과 같은 물리화학적 성상을 나타내어 이를 컴파운드 K로 동정하였다. 컴파운드 K의 물리화학적 성상은 다음과 같다.Hereinafter, the method for preparing Compound K according to the present invention will be described in detail. Ginsenosides Rb 1 , Rb 2 , Rc, Rd or mixtures thereof and ginseng extracts having a high content ratio thereof are dissolved in an aqueous solvent or a mixture of an aqueous solvent and an organic solvent, and cellulase derived from the microorganism penicillium or Beta-galactosidase isolated from Aspergillus was added thereto, reacted for 1 to 72 hours at 20 to 60 ° C, and heated in a boiling water bath for 10 minutes to inactivate the enzyme to obtain a reaction solution containing a large amount of Compound K. According to the enzymatic method, conventionally, a high-purity ginsenoside standard was prepared by reacting with enzymes hesperidinase, naringinase, pectinase, or obtained by separating and preparing the intestinal metabolite of saponin. Ginsenosides Rb 1 , Rb 2 , Rc, and Rd, which are the substrates of the enzymes, have not been subjected to the difficult process of separating high purity products, and the enzymes isolated from the enzyme cellulase or Aspergillus isolated from the penicillium Reaction with phosphorus beta-galactosidase has the advantage of easy separation because only compound K is produced in a short period of time. The product prepared according to the present invention exhibited the following physical and chemical properties and was identified as Compound K. The physical and chemical properties of Compound K are as follows.
성상: 백색 무정형 분말(에탄올),녹는점: 176-178oC, [alpha]D 22: +9.3°( c=0.90, CHCℓ3),Rf값: 키젤겔 60 F254박층크로마토그래피를 이용하여 클로로포름-메탄올-물(=65:35:10, 아래층)로 전개하였을 때 0.65, Constellation: White amorphous powder (ethanol),Melting point: 176-178oC, [alpha]D 22: + 9.3 ° (c = 0.90, CHCℓ3),Rf value: Kiesel Gel 60 F2540.65, when developed with chloroform-methanol-water (= 65: 35: 10, lower layer) using thin layer chromatography
고속원자 충격 질량 스펙트럼(negative): m/z 621.6〔C36H62O8-H〕-, 459.4〔C36H62O8-Glc-H〕- Fast atom bombardment mass spectra : m / z 621.6 [C 36 H 62 O 8 -H] - , 459.4 [C 36 H 62 O 8 -Glc-H] -
수소 핵자기공명 스펙트럼(δ): 3.42(1H, dd, J=10.5, 5.1 Hz, H-3), 0.82(1H, d, J=11.1, Hz, H-5), 4.19(1H, dd, H-12), 5.25(1H, t, J=6.8, 1 Hz, H-24), 0.90(3H, s, Me-18), 0.90(3H, s, Me-19), 1.57(3H, s, Me-21), 1.60(3H, s, Me-26), 1.60(3H, s, Me-27), 1.23(3H, s, Me-28), 1.02(3H, s, Me-29), 0.95(3H, s, Me-30), 5.19(1H, d, J=7.2, H-1'-20-Glc) Hydrogen nuclear magnetic resonance spectrum (δ) : 3.42 (1H, dd, J = 10.5, 5.1 Hz, H-3), 0.82 (1H, d, J = 11.1, Hz, H-5), 4.19 (1H, dd, H-12), 5.25 (1H, t, J = 6.8, 1 Hz, H-24), 0.90 (3H, s, Me-18), 0.90 (3H, s, Me-19), 1.57 (3H, s Me-21), 1.60 (3H, s, Me-26), 1.60 (3H, s, Me-27), 1.23 (3H, s, Me-28), 1.02 (3H, s, Me-29), 0.95 (3H, s, Me-30), 5.19 (1H, d, J = 7.2, H-1'-20-Glc)
탄소 핵자기공명 스펙트럼(δ): 15.99, 16.29, 16.32, 17.36, 17.72, 18.73, 22.29, 23.14, 25.72, 26.60, 28.22, 28.65, 30.74, 30.91, 35.13, 36.13, 37.32, 39.37, 39.51, 40.03, 49.47, 50.27, 51.38, 51.56, 56.33, 62.86, 70.11, 71.62, 75.06, 78.01, 78.19, 79.25, 83.24, 98.20, 125.92, 130.85 Carbon nuclear magnetic resonance spectra (δ) : 15.99, 16.29, 16.32, 17.36, 17.72, 18.73, 22.29, 23.14, 25.72, 26.60, 28.22, 28.65, 30.74, 30.91, 35.13, 36.13, 37.32, 39.37, 39.51, 40.03, 49.47 , 50.27, 51.38, 51.56, 56.33, 62.86, 70.11, 71.62, 75.06, 78.01, 78.19, 79.25, 83.24, 98.20, 125.92, 130.85
이하 본 발명을 보다 상세히 설명하면 다음의 실시예와 같다. 다만 이들 실시예가 본 발명의 기술적 범위를 한정하는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples do not limit the technical scope of the present invention.
<실시예 1><Example 1>
진세노사이드 Rb11g을 0.1M 초산완충용액(pH 5.0)에 용해시켜 전체를 50㎖로 정용한 다음 여기에 페니실리움속에서 분리한 셀룰라제 3g을 첨가하여 37℃ 수욕조상에서 교반하면서 48시간 반응시킨다. 박층크로마토그래피에 의해 주기적으로 확인하여 기질이 완전히 소실되면 열수중에서 10분간 가열하여 반응을 종료시킨 다음 다이아이온 HP-20 수지를 충진한 컬럼에 흡착시킨 후 당류와 효소는 증류수로 세척하여 제거하고 반응생성물은 메탄올로 용출한후 농축시켜 컴파운드 K가 85% 이상 함유된 분말상 반응생성물을 얻었다. 1 g of ginsenoside Rb 1 was dissolved in 0.1 M acetic acid buffer solution (pH 5.0), and the whole was basified to 50 ml. Then, 3 g of cellulase separated in penicillium was added thereto and stirred in a 37 ° C. water bath for 48 hours. React. After periodic confirmation by thin layer chromatography, when the substrate is completely lost, the reaction is terminated by heating in hot water for 10 minutes, and then adsorbed on the column filled with DIION HP-20 resin, and then the saccharides and enzymes are removed by washing with distilled water. The product was eluted with methanol and concentrated to give a powdery reaction product containing more than 85% of compound K.
<실시예 2><Example 2>
진세노사이드 Rb21g을 초산완충용액(pH 4.8)에 용해시켜 전체를 50㎖로 정용한 다음 아스퍼질러스속에서 분리한 베타-갈락토시다제 3g을 첨가하여 45℃ 수욕조상에서 교반하면서 72시간 반응시킨다. 반응액은 열수중에서 10분간 가열하여 반응을 종료시킨 다음 수포화 부탄올로 추출, 농축하여 컴파운드 K가 85% 이상 함유된 반응생성물을 얻었다.1 g of ginsenoside Rb 2 was dissolved in acetic acid buffer solution (pH 4.8), and the whole was applied to 50 ml, followed by addition of 3 g of beta-galactosidase isolated from Aspergillus, followed by 72 hours of stirring in a 45 ° C. water bath. Let's do it. The reaction solution was heated in hot water for 10 minutes to complete the reaction, followed by extraction and concentration with saturated butanol to obtain a reaction product containing 85% or more of compound K.
<실시예 3><Example 3>
진세노사이드 Rc 1g을 인산완충용액(pH 5.0)에 용해시켜 전체를 50㎖로 정용한 다음 여기에 페니실리움속에서 분리한 셀룰라제 4g을 첨가하여 37℃ 수욕조상에서 교반하면서 72시간 반응시킨다. 반응액은 열수중에서 10분간 가열하여 반응을 종료시킨 다음 수포화 부탄올로 추출, 농축하여 분말상의 반응생성물 750㎎을 얻었다. 농축액은 실리카겔 컬럼크로마토그래피(클로로포름-메탄올-물=70:30:5)와 역상 RP-8 컬럼 크로마토그래피(85% 메탄올)로 컴파운드 K 425㎎을 얻었다.1 g of ginsenoside Rc was dissolved in a phosphate buffer solution (pH 5.0), and the whole was subjected to 50 ml. Then, 4 g of cellulase separated in penicillium was added thereto and reacted for 72 hours while stirring in a 37 ° C. water bath. The reaction solution was heated in hot water for 10 minutes to complete the reaction, followed by extraction with saturated butanol to give 750 mg of powdered reaction product. The concentrate was subjected to silica gel column chromatography (chloroform-methanol-water = 70: 30: 5) and reverse phase RP-8 column chromatography (85% methanol) to obtain Compound K 425 mg.
<실시예 4><Example 4>
진세노사이드 Rd 1g을 시트레이트 완충용액(pH 5.0)에 용해시켜 전체를 50㎖로 정용한 다음 아스퍼질러스속에서 분리한 베타-갈락토시다제 5g을 첨가하여 50℃ 수욕조상에서 교반하면서 72시간 반응시킨다. 반응액은 열수중에서 10분간 가열하여 반응을 종료시킨 다음 다이아이온 HP-20 수지를 충진한 컬럼에 흡착시킨 후 증류수로 세척하고 메탄올로 용출시켜 농축한다. 농축액은 실리카겔 컬럼 크로마토그래피(클로로포름-메탄올=87:13) 에 의해 컴파운드 K 478mg을 얻었다.1 g of ginsenoside Rd was dissolved in citrate buffer (pH 5.0), and the whole solution was allowed to settle to 50 ml, and 5 g of beta-galactosidase isolated from Aspergillus was added, followed by 72 hours of stirring in a 50 ° C water bath. Let's do it. The reaction solution was heated in hot water for 10 minutes to terminate the reaction, and then adsorbed onto a column packed with DIION HP-20 resin, washed with distilled water, eluted with methanol and concentrated. The concentrated solution obtained compound K 478 mg by silica gel column chromatography (chloroform-methanol = 87:13).
<실시예 5>Example 5
진세노사이드 Rb1, Rb2, Rc, Rd의 동량 혼합물 1g을 시트레이트- 인산완충용액(pH 5.0)에 용해시켜 전체를 50㎖로 정용한 다음 페니실리움속에서 분리한 셀룰라제 4g을 첨가하여 50℃ 수욕조상에서 교반하면서 72시간 반응시킨다. 반응액은 열수중에서 10분간 가열하여 반응을 종료시킨 다음 수포화 부탄올로 추출, 농축한다. 농축액은 실리카겔 컬럼 크로마토그래피(클로로포름-메탄올=9:1)에 의해 컴파운드 K 455 mg을 얻었다. 1 g of a mixture of the same amount of ginsenosides Rb 1 , Rb 2 , Rc, and Rd was dissolved in citrate-phosphate buffer solution (pH 5.0), the whole was basified to 50 ml, and then 4 g of cellulase separated from penicillium was added. It is made to react for 72 hours, stirring in a 50 degreeC water bath. The reaction solution is heated in hot water for 10 minutes to complete the reaction, followed by extraction with saturated butanol and concentration. The concentrate was subjected to silica gel column chromatography (chloroform-methanol = 9: 1) to obtain 455 mg of compound K.
<실시예 6><Example 6>
다이올계 사포닌이 주로 함유된 인삼근에서 분리한 조사포닌 분획 1g을 초산 완충용액(pH 5.0)에 용해시켜 전체를 50㎖로 정용한 다음 여기에 아스퍼질러스속에서 분리한 베타-갈락토시다제 3g을 첨가하여 37℃의 수욕조상에서 교반하면서 48시간 반응시킨다. 반응액은 열수중에서 가열하여 반응을 종료시킨 다음 수포화 부탄올로 추출후, 감압 농축한다. 농축액은 실리카겔 컬럼 크로마토그래피(클로로포름-메탄올=9:1)에 의해 컴파운드 K 326mg을 얻었다.Dissolve 1 g of irradiated saponin fraction in ginseng root containing predominantly diol-based saponin in acetic acid buffer (pH 5.0), apply the whole amount to 50 ml, and add 3 g of beta-galactosidase isolated from Aspergillus. The mixture is added and reacted for 48 hours with stirring in a 37 ° C water bath. The reaction solution is heated in hot water to terminate the reaction, extracted with saturated butanol and concentrated under reduced pressure. The concentrate was subjected to silica gel column chromatography (chloroform-methanol = 9: 1) to obtain compound K 326 mg.
<실시예 7><Example 7>
인삼 추출엑스 1g을 물에 용해시켜 전체를 50㎖로 정용한 다음 여기에 아스퍼질러스속에서 분리한 베타-갈락토시다제 3g을 첨가하여 37℃에서 48시간 반응시킨다. 반응액은 열수중에서 가열하여 효소를 불활성화시킨 다음 다이아이온 HP-20 수지를 충진한 컬럼에 흡착시킨 후 증류수로 세척하여 당류와 효소류를 제거하고 반응생성물은 메탄올로 용출시켜 농축한다. 농축액은 실리카겔 컬럼 크로마토그래피(클로로포름-메탄올=87:13)로 분리하여 컴파운드 K가 60% 이상 함유된 분말상 반응생성물을 얻었다.1 g of ginseng extract extract was dissolved in water, and the whole was applied to 50 ml. Then, 3 g of beta-galactosidase isolated from Aspergillus was added thereto and reacted at 37 ° C. for 48 hours. The reaction solution is heated in hot water to inactivate the enzyme, adsorbed onto a column filled with DIION HP-20 resin, washed with distilled water to remove sugars and enzymes, and the reaction product is eluted with methanol and concentrated. The concentrate was separated by silica gel column chromatography (chloroform-methanol = 87: 13) to obtain a powdery reaction product containing at least 60% of compound K.
본 발명은 페니실리움속에서 분리한 셀룰라제 또는 아스퍼질러스속에서 분리한 베타-갈락토시다제를 인삼에 다량 함유되어 있는 주요 다이올계 사포닌인 진세노사이드 Rb1,Rb2, Rc, Rd 또는 이들의 혼합물과 효소적 방법으로 반응시켜 제조수율 75% 이상의 고수율로 컴파운드 K를 간단하게 대량으로 제조하는 데 있다.The present invention relates to ginsenosides Rb 1, Rb 2 , Rc, Rd, which are major diol-based saponins containing a large amount of cellulase isolated from penicillium or beta-galactosidase isolated from Aspergillus. The compound K is reacted by an enzymatic method with a mixture of these compounds to produce a large amount of compound K simply in high yield of 75% or more.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0043170A KR100377546B1 (en) | 2000-07-26 | 2000-07-26 | Manufacturing Method for Ginsenoside Compound K by Enzymatic Reaction |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0043170A KR100377546B1 (en) | 2000-07-26 | 2000-07-26 | Manufacturing Method for Ginsenoside Compound K by Enzymatic Reaction |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020009756A true KR20020009756A (en) | 2002-02-02 |
KR100377546B1 KR100377546B1 (en) | 2003-03-26 |
Family
ID=19680144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0043170A KR100377546B1 (en) | 2000-07-26 | 2000-07-26 | Manufacturing Method for Ginsenoside Compound K by Enzymatic Reaction |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100377546B1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100403570B1 (en) * | 2000-12-29 | 2003-10-30 | 주식회사 케이티앤지 | Method for the Production of Ginsenoside F2 by Enzymatic Process |
KR20030094757A (en) * | 2002-06-07 | 2003-12-18 | 주식회사 비티진 | Process for preparation of ginsenoside-F2, Compound-K using β-glycosidase |
KR100412218B1 (en) * | 2001-07-24 | 2003-12-24 | 주식회사 일화 | METHOD FOR PRODUCING 20-O-β-D-GLUCOPYRANOSIL-20(S)-PROTOPANAXADIOL |
KR100418604B1 (en) * | 2001-11-01 | 2004-02-11 | 주식회사 태평양 | Manufacturing method of Compound K and Ginsenoside F1 from ginseng ginsenosides |
KR100420451B1 (en) * | 2001-11-27 | 2004-03-02 | 주식회사 케이티앤지 | The manufacturing method for ginsenoside compound k with cellulase or lactase composition y-ao |
KR100465977B1 (en) * | 2002-01-05 | 2005-01-13 | 주식회사 태평양 | Nanoemulsion having Compound K by nano-emulsion technology, and skin care and pharmaceutical compositions for external applications utilizing thereof |
KR100533505B1 (en) * | 2005-04-29 | 2005-12-06 | 김동현 | Health supplement food containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease |
KR100551564B1 (en) * | 2002-04-08 | 2006-02-13 | 김동현 | Composition containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease |
KR100654172B1 (en) * | 2005-05-27 | 2006-12-06 | 주식회사 비티진 | A preparation method of ginsenoside Mc and Mc-1 |
KR100689745B1 (en) * | 2005-05-23 | 2007-03-08 | 주식회사 비티진 | A preparation method for ginsenosides using ?-galactosidase |
WO2010134650A1 (en) | 2009-05-19 | 2010-11-25 | Il Hwa Co., Ltd. | Methods for preparing a fermented ginseng concentrate or powder |
WO2011059212A2 (en) * | 2009-11-12 | 2011-05-19 | Cj Cheiljedang Corporation | Preparation method of ginseng and red ginseng concentrates containing the increased amount of compound k by using pectinex |
CN103073611A (en) * | 2013-01-10 | 2013-05-01 | 天津大学 | Ginsenoside C-K semihydrate crystal and preparation method thereof |
WO2013109062A1 (en) * | 2012-01-20 | 2013-07-25 | 씨제이제일제당(주) | Saponin metabolite compound k-reinforced fraction using enzymatic conversion and fractionation, and preparation method thereof |
US8541035B2 (en) | 2009-05-14 | 2013-09-24 | Il Hwa Co., Ltd. | Methods for preparing a fermented ginseng concentrate or powder |
US8574639B2 (en) | 2010-08-17 | 2013-11-05 | ILHWA Co., Ltd. | Fermented ginseng concentrate having IH-901 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100444370B1 (en) * | 2001-11-27 | 2004-08-16 | 주식회사 한국인삼공사 | The manufacturing method for ginsenoside f1 with naringinase |
KR100877489B1 (en) * | 2007-04-19 | 2009-01-08 | 메타볼랩(주) | Enzymatic Conversion of Ginsenosides |
KR100921257B1 (en) | 2007-08-31 | 2009-10-13 | 주식회사 케이티앤지 | Method for production of ginsenoside comprising Compound K |
KR101597877B1 (en) | 2013-09-11 | 2016-02-25 | 주식회사 동원에프앤비 | Extracting method of effective component from ginsenosides |
KR102655938B1 (en) | 2016-09-28 | 2024-04-11 | (주)아모레퍼시픽 | Composition for producing ginsenoside compound K comprising thermo satble alpha-L-arabinofuranosidase enzyme and preparation method of ginsenoside compound K |
KR20220036435A (en) | 2020-09-15 | 2022-03-23 | 아미코젠주식회사 | Novel Aspergillus niger AG1 and a method of producing compound K using the same |
KR102346868B1 (en) | 2021-05-26 | 2022-01-04 | 대동고려삼 주식회사 | Production process with enhanced specific component of red ginseng hydrolysis concentrate |
-
2000
- 2000-07-26 KR KR10-2000-0043170A patent/KR100377546B1/en active IP Right Grant
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100403570B1 (en) * | 2000-12-29 | 2003-10-30 | 주식회사 케이티앤지 | Method for the Production of Ginsenoside F2 by Enzymatic Process |
KR100412218B1 (en) * | 2001-07-24 | 2003-12-24 | 주식회사 일화 | METHOD FOR PRODUCING 20-O-β-D-GLUCOPYRANOSIL-20(S)-PROTOPANAXADIOL |
KR100418604B1 (en) * | 2001-11-01 | 2004-02-11 | 주식회사 태평양 | Manufacturing method of Compound K and Ginsenoside F1 from ginseng ginsenosides |
KR100420451B1 (en) * | 2001-11-27 | 2004-03-02 | 주식회사 케이티앤지 | The manufacturing method for ginsenoside compound k with cellulase or lactase composition y-ao |
KR100465977B1 (en) * | 2002-01-05 | 2005-01-13 | 주식회사 태평양 | Nanoemulsion having Compound K by nano-emulsion technology, and skin care and pharmaceutical compositions for external applications utilizing thereof |
KR100551564B1 (en) * | 2002-04-08 | 2006-02-13 | 김동현 | Composition containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease |
KR20030094757A (en) * | 2002-06-07 | 2003-12-18 | 주식회사 비티진 | Process for preparation of ginsenoside-F2, Compound-K using β-glycosidase |
KR100533505B1 (en) * | 2005-04-29 | 2005-12-06 | 김동현 | Health supplement food containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease |
KR100689745B1 (en) * | 2005-05-23 | 2007-03-08 | 주식회사 비티진 | A preparation method for ginsenosides using ?-galactosidase |
KR100654172B1 (en) * | 2005-05-27 | 2006-12-06 | 주식회사 비티진 | A preparation method of ginsenoside Mc and Mc-1 |
US8541035B2 (en) | 2009-05-14 | 2013-09-24 | Il Hwa Co., Ltd. | Methods for preparing a fermented ginseng concentrate or powder |
WO2010134650A1 (en) | 2009-05-19 | 2010-11-25 | Il Hwa Co., Ltd. | Methods for preparing a fermented ginseng concentrate or powder |
EP2432891A1 (en) * | 2009-05-19 | 2012-03-28 | Il Hwa Co., Ltd. | Methods for preparing a fermented ginseng concentrate or powder |
EP2432891A4 (en) * | 2009-05-19 | 2015-04-22 | Il Hwa Co Ltd | Methods for preparing a fermented ginseng concentrate or powder |
WO2011059212A2 (en) * | 2009-11-12 | 2011-05-19 | Cj Cheiljedang Corporation | Preparation method of ginseng and red ginseng concentrates containing the increased amount of compound k by using pectinex |
WO2011059212A3 (en) * | 2009-11-12 | 2011-09-29 | Cj Cheiljedang Corporation | Preparation method of ginseng and red ginseng concentrates containing the increased amount of compound k by using pectinex |
US8574639B2 (en) | 2010-08-17 | 2013-11-05 | ILHWA Co., Ltd. | Fermented ginseng concentrate having IH-901 |
WO2013109062A1 (en) * | 2012-01-20 | 2013-07-25 | 씨제이제일제당(주) | Saponin metabolite compound k-reinforced fraction using enzymatic conversion and fractionation, and preparation method thereof |
CN103073611A (en) * | 2013-01-10 | 2013-05-01 | 天津大学 | Ginsenoside C-K semihydrate crystal and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR100377546B1 (en) | 2003-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100377546B1 (en) | Manufacturing Method for Ginsenoside Compound K by Enzymatic Reaction | |
CN105648021B (en) | The preparation method of ginseng rare saponin(e C-K, F1 and four kinds of isomers ginsengenins | |
Dubois et al. | Cussonosides A and B, two triterpene-saponins from Cussonia barteri | |
KR100418604B1 (en) | Manufacturing method of Compound K and Ginsenoside F1 from ginseng ginsenosides | |
Gong et al. | Chemical components of Ganoderma | |
CN104232498B (en) | A kind of fine bacteria strain of fibrosis fiber and application thereof | |
CN112300242B (en) | Preparation method of furostanol saponin compound monomer | |
Sofrenić et al. | Cytotoxic triterpenoids and triterpene sugar esters from the medicinal mushroom Fomitopsis betulina | |
KR100293968B1 (en) | 20 (S) - Production method of Ginsenoside AL | |
Li et al. | Molecular networking-based strategy for the discovery of polyacetylated 18-norspirostanol saponins from Trillium tschonoskii maxim. | |
KR100424438B1 (en) | Enzymatic producing method of ginsenoside rd | |
KR20080028266A (en) | Method for production of compound k, and compound y, ginsenoside f1 from ginseng using hydrolytic enzymes, pectinex and viscozyme | |
KR100403570B1 (en) | Method for the Production of Ginsenoside F2 by Enzymatic Process | |
KR100420451B1 (en) | The manufacturing method for ginsenoside compound k with cellulase or lactase composition y-ao | |
Gebhardt et al. | Biocatalytic Generation of Molecular Diversity: Modification of Ginsenoside Rb1 by β‐1, 4‐Galactosyltransferase and Candida antarctica Lipase, Part 4 | |
KR100218553B1 (en) | Process for producing ginsenoside rg3 | |
KR101959848B1 (en) | Method of producing rare ginseng saponin by using Formitella fracinea mycelia | |
KR100249427B1 (en) | Ginsenoside re-beta-d-xylosides and producing method thereof | |
KR101802979B1 (en) | Mehod for producing ginsenoside F1 using bioconversion | |
KR100186757B1 (en) | Preparation process of 20(s)-ginsenocide rh1 and 20(s)-protopanaxtrlyol | |
TWI770498B (en) | Fungal triterpenoid glucoside compound and preparation method thereof | |
Rosselli et al. | Furostanol saponins and ecdysones with cytotoxic activity from Helleborus bocconei ssp. intermedius | |
He et al. | Microbial transformation of methyl protodioscin by Cunninghamella elegans | |
KR100444370B1 (en) | The manufacturing method for ginsenoside f1 with naringinase | |
KR100689745B1 (en) | A preparation method for ginsenosides using ?-galactosidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130218 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140227 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20150223 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170303 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20180227 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20190305 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20200204 Year of fee payment: 18 |